| 13.24 0.05 (0.38%) | 08-19 11:13 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 15.78 |
1-year : | 18.43 |
| Resists | First : | 13.51 |
Second : | 15.78 |
| Pivot price | 12.49 |
|||
| Supports | First : | 11.79 |
Second : | 10.72 |
| MAs | MA(5) : | 13.1 |
MA(20) : | 12.14 |
| MA(100) : | 19.21  |
MA(250) : | 20.89 |
|
| MACD | MACD : | 0 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 95.9 |
D(3) : | 92 |
| RSI | RSI(14): 61.4 |
|||
| 52-week | High : | 34.47 | Low : | 10.52 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ OCS ] has closed below upper band by 13.9%. Bollinger Bands are 64% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 41 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 13.22 - 13.27 | 13.27 - 13.32 |
| Low: | 12.76 - 12.82 | 12.82 - 12.88 |
| Close: | 13.09 - 13.18 | 13.18 - 13.28 |
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
Fri, 14 Aug 2026
The Technical Signals Behind (OCS) That Institutions Follow - Stock Traders Daily
Fri, 14 Aug 2026
Four Oculis directors' restricted stock units vest in Aug. 13 notifications - Stock Titan
Fri, 14 Aug 2026
Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect? - Zacks Investment Research
Tue, 11 Aug 2026
Oculis Announces Asset Purchase Agreement With Accure Therapeutics, Posts Q2 2026 Financial Results - VisionMonday.com
Fri, 07 Aug 2026
Oculis Holding AG (OCS) Stock Analysis: Navigating a 190.92% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Thu, 06 Aug 2026
Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates - finance.yahoo.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 5.212e+007 (%) |
| Held by Institutions | 3.5 (%) |
| Shares Short | 1,100 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.324e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -10 % |
| Return on Assets (ttm) | 396.1 % |
| Return on Equity (ttm) | -23.3 % |
| Qtrly Rev. Growth | 1.12e+006 % |
| Gross Profit (p.s.) | -121.37 |
| Sales Per Share | -239.37 |
| EBITDA (p.s.) | -2.51091e+008 |
| Qtrly Earnings Growth | -1.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -63 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.06 |
| Price to Cash Flow | 0.73 |
| Dividend | 0 |
| Forward Dividend | 1.51e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|